Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

NVIDIA

Generate:Biomedicines said it has raised $273 million to fund its pipeline of programs in preclinical and clinical development across oncology, immunology, and infectious disease, including filing multiple Investigational New Drug (IND) applications with the Food and Drug Administration (FDA) and initiating multiple clinical trials annually. The Somerville, Massachusetts-based firm, which uses a machine learning-powered generative biology platform for drug generation, said the Series C fundraising attracted new investors, notably NVIDIA Corporation (NASDAQ:NVDA)'s venture capital arm NVentures, Amgen, Inc. (NASDAQ:AMGN), MAPS Capital (Mirae Asset Group) and Pictet Alternative Advisors.

Nvidia and Amgen back AI drug developer Generate:Biomedicines' $273M financing

Drug developer Generate:Biomedicines, which uses artificial intelligence (AI) to find new treatments, said on Thursday it has raised $273 million from investors including Nvidia's venture capital arm and Amgen.

Nvidia, Amgen back AI-driven drug firm Generate:Biomedicines' $273 mln fundraise

American Express

Dividend stocks can be powerful capital appreciation vehicles. Amgen and American Express both screen as top-notch dividend stocks to buy and hold for the long term.

2 Top Dividend Stocks to Buy in September

CVS Health

Medtronic

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - CVS Health (NYSE:CVS), Amgen (NASDAQ:AMGN)

Moderna

Pfizer

It's been a difficult time for biotechnology stocks. After a boom during the Covid-19 pandemic, the entire sector appears to have been abandoned by investors.

The 3 Most Undervalued Biotech Stocks to Buy in September 2023

Amgen Inc. (NASDAQ:AMGN ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 12, 2023 8:50 AM ET Company Participants Robert Bradway - Chairman and Chief Executive Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Good morning, everybody.

Amgen Inc. (AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)

Honeywell

We believe that Honeywell stock (NYSE: HON) and Amgen stock (NASDAQ: AMGN) will offer little returns in the next three years.

Which Is A Better Pick – Honeywell Stock Or Amgen?

AbbVie

Bristol-Myers

Cardinal Health

Gilead Sciences

The strong move higher that Nvidia has driven in the stock market this year has been significant, and the world of artificial intelligence has driven stock prices this year.

Big Institutions Grab ‘Strong Buy' Dividend Stocks in a Sector Not Totally Driven by AI

In Phase 1b Study, Patients Treated in First-Line Demonstrated a Confirmed Objective Response Rate of 65% THOUSAND OAKS, Calif. , Sept. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC

THOUSAND OAKS, Calif. , Sept. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 8:50 a.m.

AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

Amgen Inc. (AMGN) Citi Global Healthcare Conference (Transcript)

Amgen could report great quarterly results with revenue, operating income and EPS growing with a solid pace. The stock is undervalued in my opinion and Amgen could be seen as a good investment. However, I think the Horizon acquisition was not the best use of cash and the high debt levels of Amgen are a red flag.

Amgen: Not An Investment Mistake, But It Was Better Before

Amgen Inc. (NASDAQ:AMGN ) Wells Fargo Securities Healthcare Conference September 6, 2023 9:30 AM ET Company Participants Arvind Sood - VP of IR Peter Griffith - EVP and CFO Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Thank you very much for joining us today. My name is Mohit Bansal.

Amgen Inc. (AMGN) Wells Fargo Securities Healthcare Conference (Transcript)

Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.

Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why

Apple

We're now into September, and that means many investors wonder if the September effect will be in place. This speaks to the historical trend of stocks underperforming in September compared to other months.

3 Growth Stocks to Buy in September

Horizon Pharma

Some analysts and M&A experts say the settlement agreement doesn't mean that the FTC will stop baring its teeth at other large buyouts in the industry.

The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals

The U.S. Federal Trade Commission's decision on Friday to allow Amgen's takeover of Horizon Therapeutics was the latest setback to its stated goal of stricter antitrust enforcement, and instead paved the way for Amgen to gain drugs not subject to new price negotiations and possibly lower the company's tax burden.

Analysis: FTC settlement could shelter Amgen from US price cuts, taxes

Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.

FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen (AMGN) is a Top-Ranked Momentum Stock: Should You Buy?

The Federal Trade Commission will allow Amgen to continue a $27.8 billion purchase of Horizon Therapeutics. The companies anticipate closing the deal in the fourth quarter.

Amgen gets green light from FTC for $27.8B Horizon Therapeutics deal

The Federal Trade Commission will allow pharmaceutical giant Amgen to move ahead with its acquisition of Horizon Therapeutics, averting a trial set for September.

Amgen settles with the FTC over $28 billion deal

The Federal Trade Commission said it had agreed to end its legal challenge of the $27.8 billion deal. The pact also dismisses the antitrust claims of six states that joined the FTC in seeking to block the transaction.

Amgen's Deal for Horizon Therapeutics Clears Key Hurdle

Shares of Horizon Therapeutics PLC (NASDAQ: HZNP) are trading materially up today after the FTC allowed Amgen Inc (NASDAQ: AMGN) to move forward with its $27.8 billion acquisition of the biopharmaceutical company.

FTC clears Amgen's $28 billion acquisition of Horizon Therapeutics

The agency previously argued the merger could harm patients who are prescribed Horizon's two fastest-growing drugs.

Amgen's $27.8 Billion Purchase Of Horizon Therapeutics On After FTC Settlement

The Federal Trade Commission makes provision that prohibits “bundling” discounts for some medications.

News for Amgen Stock (AMGN)